НовостиBenzingaWedbush Reiterates Outperform on Damora Therapeutics, Maintains $40 Price Target Wedbush Reiterates Outperform on Damora Therapeutics, Maintains $40 Price Target Benzinga 2026.09.29 12:20 (GMT+0) Открыть на Benzinga Другие новости